Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > BUSINESS
BUSINESS
- GSK Submits NDA for Pazopanib in Japan
December 14, 2011
- MTPC to Focus on Development of Global Human Resources
December 14, 2011
- Eisai Files Application for New Aricept Dry Syrup Formulation
December 14, 2011
- SGN-35 for Treatment-naïve Lymphoma to Progress to PIII: Takeda
December 14, 2011
- Substance Patent for Therapeutic Protein Delivery Allowed in US: NanoCarrier
December 14, 2011
- PI/II Results Confirm Safety, Tolerability of Oral Proteasome Inhibitor: Takeda
December 14, 2011
- 86% of Patients Show Objective Responses in PII Trial of CD30 Monoclonal Antibody: Takeda
December 14, 2011
- Mochida Pharmaceutical Grants Rights for Diabetes Treatment to US Merck
December 13, 2011
- Kissei Pharmaceutical to Transfer Marketing Rights for CABASER to Pfizer Japan
December 13, 2011
- Otsuka's US Subsidiary CEO to Become New President, Taiho Pharmaceutical
December 13, 2011
- Wholesalers Eager to Begin Category-Based Price Negotiations After FY2012 Price Revision
December 13, 2011
- Ohara Pharmaceutical to Initiate Clinical Trials for Leukemia Treatment Drug Requested for Development
December 13, 2011
- OncoTherapy’s Subsidiary Immunas Receives Milestone Payment from Kyowa Hakko Kirin
December 13, 2011
- EC Grants Marketing Authorization for Takeda’s ARB Edarbi
December 12, 2011
- Fuso Withdraws NDA for PHN Treatment in Japan, Prepares for Additional Studies
December 12, 2011
- Will Ilaris Remain an “Ultra-orphan” Drug?
December 10, 2011
- DODA Survey Shows MR’s Average Annual Income at ¥6.61 Million, 6th Highest by Occupation
December 9, 2011
- GSK’s Ofatumumab and Pazopanib Granted Orphan Drug Designation
December 9, 2011
- Kyowa Kirin Aims to Make RNAi Drugs Future Pillar: Dr Shitara
December 9, 2011
- Kobayashi, President of Mitsubishi Chemical HD Expects Continuous Growth of Pharmaceutical Business
December 9, 2011
ページ
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…